Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
Saturday, May 17, 2014 - 19:00
in Health & Medicine
The results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis have been published, demonstrating positive trends in both the primary endpoint, lung function as measured by relative change in percent predicted FEV1 (forced expiratory volume in one second) and in the secondary outcome measure, rate of pulmonary exacerbations.